c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis

British Journal of Cancer

Volumn 89, Issue 9, 2003, Pages 1757-1765

  Arango, D ^a,b   Mariadason, J M ^a   Wilson, A J ^a   Yang, W ^a   Corner, G A ^a   Nicholas, C ^a   Aranes, M J ^a   Augenlicht, L H ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Apoptosis; Camptothecin; Microarray; p21Waf1 Cip1

Indexed keywords

CAMPTOTHECIN; COMPLEMENTARY DNA; MYC PROTEIN; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA MICROARRAY; DNA REPAIR; DRUG RESISTANCE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL;

EID: 0344009714     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601338     Document Type: Article

References (41)

1. Arango D, Augenlicht LH (2001) New approaches to colorectal cancer treatment. In Recent Research Developments in Cancer, Vol. 3 pp 385-395. Trivandrum: Transworld Research Network
2. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH (2001) c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 61: 4910-4915
3. Arango D, Wilson AJ, Mariadason JM, Corner GA, Aran̄es MJ, Nicholas C, Augenlicht LH (2003) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. (submitted)
4. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769-1775
5. Augeron C, Laboisse CL (1984) Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 44: 3961-3969
6. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501
7. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet 352: 1413-1418
8. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11
9. Datto MB, Yu Y, Wang XF (1995) Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270: 28623-28628
10. Devine PL, Birrell GW, Whitehead RH, Harada H, Xing PX, McKenzie IF (1992) Expression of MUC1 and MUC2 mucins by human tumor cell lines. Tumour Biol 13: 268-277
11. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
13. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM (1985) Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 5: 1969-1976
14. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL (2001) Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 98: 4510-4515
15. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y (1997) Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res 3: 1653-1660
16. Harvey J, Bonnem E, Grady K, Goodman A, Schein P (1985) Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma. Med Pediatr Oncol 13: 30-31
17. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737
18. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Schwanz EL, Lesser M (2003) Gene expression profiling based prediction of response of colon carcinoma cells to chemotherapeutic agents. Cancer Res (in press)
19. Mariadason JM, Corner GA, Augenlicht LH (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60: 4561-4572
20. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM (1997) Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8: 1039-1048
21. Menssen A, Hermeking H (2002) Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99: 6274-6279
22. Mitchell KO, El-Deiry WS (1999) Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in12-O-tetradecanoylphorbol- 13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10: 223-230
23. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805
24. O'Dwyer PJ, Stevenson JP (1998) Chemotherapy of advanced colorectal cancer. In Gastrointestinal Oncology, Cancer Treatment and Research, Benson AL (ed) pp 111-152. Norwell: Kluwer Academic Publishers
25. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658
26. Prendergast GC (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987
27. Reed JC, Haldar S, Cuddy MP, Croce C, Makover D (1989) Deregulated BCL2 expression enhances growth of a human B cell line. Oncogene 4: 1123-1127
28. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN (2003) Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 63: 1000-1011
29. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V (1993) c-Myc transactivates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4: 57-65
30. Saadat I, Saadat M (2001) Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers. Cancer Lett 169: 21-26
31. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327
32. Seoane J, Le HV, Massague J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734
33. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson Jr JR, Elkahloun AG (1999) In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59: 5656-5661
34. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304
35. Tavtigian SV, Zabludoff SD, Wold BJ (1994) Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression. Mol Biol Cell 5: 375-388
36. Tibbetts LM, Chu MY, Vezeridis MP, Miller PG, Tibbetts LL, Poisson MH, Camara PD, Calabresi P (1988) Cell culture of the mucinous variant of human colorectal carcinoma. Cancer Res 48: 3751-3759
37. Tikhonenko AT, Black DJ, Linial ML (1996) Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 271: 30741-30747
38. Whitehead RH, Macrae FA, St John DJ, Ma J (1985) A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst 74: 759-765
39. Yang B, Eshleman JR, Berger NA, Markowitz SD (1996) Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649-1657
40. Yuen ST, Wong MP, Chung LP, Chan SY, Cheung N, Ho J, Leung SY (1998) Up-regulation of lysozyme production in colonic adenomas and adenocarcinomas. Histopathology 32: 126-132
41. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433